Top

Molecular Cancer

Published in:

Open Access 01-12-2007 | Research

Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markers

Authors: Christina E Hoei-Hansen, Sigrid M Kraggerud, Vera M Abeler, Janne Kærn, Ewa Rajpert-De Meyts, Ragnhild A Lothe

Published in: Molecular Cancer | Issue 1/2007

Abstract

Background

Ovarian germ cell tumours (OGCTs) typically arise in young females and their pathogenesis remains poorly understood. We investigated the origin of malignant OGCTs and underlying molecular events in the development of the various histological subtypes of this neoplasia.

Results

We examined in situ expression of stem cell-related (NANOG, OCT-3/4, KIT, AP-2γ) and germ cell-specific proteins (MAGE-A4, NY-ESO-1, TSPY) using a tissue microarray consisting of 60 OGCT tissue samples and eight ovarian small cell carcinoma samples. Developmental pattern of expression of NANOG, TSPY, NY-ESO-1 and MAGE-A4 was determined in foetal ovaries (gestational weeks 13–40). The molecular genetic part of our study included search for the presence of Y-chromosome material by fluorescence in situ hybridisation (FISH), and mutational analysis of the KIT oncogene (exon 17, codon 816), which is often mutated in testicular GCTs, in a subset of tumour DNA samples. We detected a high expression of transcription factors related to the embryonic stem cell-like pluripotency and undifferentiated state in OGCTs, but not in small cell carcinomas, supporting the view that the latter do not arise from a germ cell progenitor. Bilateral OGCTs expressed more stem cell markers than unilateral cases. However, KIT was mutated in 5/13 unilateral dysgerminomas, whereas all bilateral dysgerminomas (n = 4) and all other histological types (n = 22) showed a wild type sequence. Furthermore, tissue from five phenotypic female patients harbouring combined dysgerminoma/gonadoblastoma expressed TSPY and contained Y-chromosome material as confirmed by FISH.

Conclusion

This study provides new data supporting two distinct but overlapping pathways in OGCT development; one involving spontaneous KIT mutation(s) leading to increased survival and proliferation of undifferentiated oogonia, the other related to presence of Y chromosome material and ensuing gonadal dysgenesis in phenotypic females.

Available only for authorised users

Nogales F, Talerman A, Kubik-Huch RA, Tavassoli FA, Devouassoux-Shisheboran M: Germ cell tumours. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Edited by: Tavassoli FA, Deville P. 2003, IARC Press,

Lu KH, Gershenson DM: Update on the management of ovarian germ cell tumors. J Reprod Med. 2005, 50: 417-425.PubMed

Riopel MA, Spellerberg A, Griffin CA, Perlman EJ: Genetic analysis of ovarian germ cell tumors by comparative genomic hybridization. Cancer Res. 1998, 58: 3105-3110.PubMed

Kraggerud SM, Szymanska J, Abeler VM, Kaern J, Eknaes M, Heim S, Teixeira MR, Trope CG, Peltomaki P, Lothe RA: DNA copy number changes in malignant ovarian germ cell tumors. Cancer Res. 2000, 60: 3025-3030.PubMed

Stettner AR, Hartenbach EM, Schink JC, Huddart R, Becker J, Pauli R, Long R, Laxova R: Familial ovarian germ cell cancer: report and review. Am J Med Genet. 1999, 84: 43-46. 10.1002/(SICI)1096-8628(19990507)84:1<43::AID-AJMG9>3.0.CO;2-2CrossRefPubMed

Galani E, Alamanis C, Dimopoulos MA: Familial female and male germ cell cancer. A new syndrome?. Gynecol Oncol. 2005, 96: 254-255. 10.1016/j.ygyno.2004.09.047CrossRefPubMed

Almstrup K, Hoei-Hansen CE, Wirkner U, Blake J, Schwager C, Ansorge W, Nielsen JE, Skakkebaek NE, Rajpert-De Meyts E, Leffers H: Embryonic stem cell-like features of testicular carcinoma in situ revealed by genome-wide gene expression profiling. Cancer Res. 2004, 64: 4736-4743. 10.1158/0008-5472.CAN-04-0679CrossRefPubMed

Rajpert-De Meyts E: Developmental model for the pathogenesis of testicular carcinoma in situ: genetic and environmental aspects. Hum Reprod Update. 2006, 12: 303-323. 10.1093/humupd/dmk006CrossRefPubMed

Molyneaux K, Wylie C: Primordial germ cell migration. Int J Dev Biol. 2004, 48: 537-544. 10.1387/ijdb.041833kmCrossRefPubMed

10.

Tian Q, Frierson HF, Krystal GW, Moskaluk CA: Activating c-kit gene mutations in human germ cell tumors. Am J Pathol. 1999, 154: 1643-1647.PubMedCentralCrossRefPubMed

11.

Przygodzki RM, Hubbs AE, Zhao FQ, O'Leary TJ: Primary mediastinal seminomas: evidence of single and multiple KIT mutations. Lab Invest. 2002, 82: 1369-1375.CrossRefPubMed

12.

Looijenga LH, de Leeuw H, van Oorschot M, van Gurp RJ, Stoop H, Gillis AJ, de Gouveia Brazao CA, Weber RF, Kirkels WJ, van Dijk T, von Lindern M, Valk P, Lajos G, Olah E, Nesland JM, Fossa SD, Oosterhuis JW: Stem cell factor receptor (c-KIT) codon 816 mutations predict development of bilateral testicular germ-cell tumors. Cancer Res. 2003, 63: 7674-7678.PubMed

13.

Sakuma Y, Sakurai S, Oguni S, Satoh M, Hironaka M, Saito K: c-kit gene mutations in intracranial germinomas. Cancer Sci. 2004, 95: 716-720. 10.1111/j.1349-7006.2004.tb03251.xCrossRefPubMed

14.

Kemmer K, Corless CL, Fletcher JA, McGreevey L, Haley A, Griffith D, Cummings OW, Wait C, Town A, Heinrich MC: KIT mutations are common in testicular seminomas. Am J Pathol. 2004, 164: 305-313.PubMedCentralCrossRefPubMed

15.

Rapley EA, Hockley S, Warren W, Johnson L, Huddart R, Crockford G, Forman D, Leahy MG, Oliver DT, Tucker K, Firedlander M, Phillips KA, Hogg D, Jewett MA, Lohynska R, Daugaard G, Richard S, Heidenreich A, Geczi L, Bodrogi I, Olah E, Ormiston WJ, Daly PA, Looijenga LH, Guilford P, Aass N, Fossa SD, Heimdal K, Tjulandin SA, Liubchenko L, Stoll H, Weber W, Einhorn L, Weber BL, McMaster M, Greene MH, Bishop DT, Easton D, Stratton MR: Somatic mutations of KIT in familial testicular germ cell tumours. Br J Cancer. 2004, 90: 2397-2401.PubMedCentralPubMed

16.

Pauls K, Wardelmann E, Merkelbach-Bruse S, Buttner R, Zhou H: c-KIT codon 816 mutation in a recurrent and metastatic dysgerminoma of a 14-year-old girl: case study. Virchows Arch. 2004, 445: 651-654. 10.1007/s00428-004-1112-3CrossRefPubMed

17.

Kamakura Y, Hasegawa M, Minamoto T, Yamashita J, Fujisawa H: C-kit gene mutation: common and widely distributed in intracranial germinomas. J Neurosurg. 2006, 104: 173-180.PubMed

18.

Lau Y, Chou P, Iezzoni J, Alonzo J, Komuves L: Expression of a candidate gene for the gonadoblastoma locus in gonadoblastoma and testicular seminoma. Cytogenet Cell Genet. 2000, 91: 160-164. 10.1159/000056838CrossRefPubMed

19.

Rajpert-De Meyts E, Jorgensen N, Graem N, Muller J, Cate RL, Skakkebaek NE: Expression of anti-Mullerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells. J Clin Endocrinol Metab. 1999, 84: 3836-3844. 10.1210/jc.84.10.3836PubMed

20.

Looijenga LH, Stoop H, de Leeuw HP, Gouveia Brazao CA, Gillis AJ, van Roozendaal KE, van Zoelen EJ, Weber RF, Wolffenbuttel KP, van Dekken H, Honecker F, Bokemeyer C, Perlman EJ, Schneider DT, Kononen J, Sauter G, Oosterhuis JW: POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res. 2003, 63: 2244-2250.PubMed

21.

Rajpert-De Meyts E, Hanstein R, Jorgensen N, Graem N, Vogt PH, Skakkebaek NE: Developmental expression of POU5F1 (OCT-3/4) in normal and dysgenetic human gonads. Hum Reprod. 2004, 19: 1338-1344. 10.1093/humrep/deh265CrossRefPubMed

22.

Hoei-Hansen CE, Almstrup K, Nielsen JE, Brask Sonne S, Graem N, Skakkebaek NE, Leffers H, Rajpert-De Meyts E: Stem cell pluripotency factor NANOG is expressed in human fetal gonocytes, testicular carcinoma in situ and germ cell tumours. Histopathology. 2005, 47: 48-56. 10.1111/j.1365-2559.2005.02182.xCrossRefPubMed

23.

Cheng L, Thomas A, Roth LM, Zheng W, Michael H, Karim FW: OCT4: a novel biomarker for dysgerminoma of the ovary. Am J Surg Pathol. 2004, 28: 1341-1346. 10.1097/01.pas.0000135528.03942.1fCrossRefPubMed

24.

Yamaguchi S, Kimura H, Tada M, Nakatsuji N, Tada T: Nanog expression in mouse germ cell development. Gene Expr Patterns. 2005, 5: 639-646. 10.1016/j.modgep.2005.03.001CrossRefPubMed

25.

Jorgensen N, Rajpert-De Meyts E, Graem N, Muller J, Giwercman A, Skakkebaek NE: Expression of immunohistochemical markers for testicular carcinoma in situ by normal human fetal germ cells. Lab Invest. 1995, 72: 223-231.PubMed

26.

Rajpert-De Meyts E, Skakkebaek NE: Expression of the c-kit protein product in carcinoma-in-situ and invasive testicular germ cell tumours. Int J Androl. 1994, 17: 85-92.CrossRefPubMed

27.

Hoei-Hansen CE, Nielsen JE, Almstrup K, Sonne SB, Graem N, Skakkebaek NE, Leffers H, Rajpert-De Meyts E: Transcription factor AP-2gamma is a developmentally regulated marker of testicular carcinoma in situ and germ cell tumors. Clin Cancer Res. 2004, 10: 8521-8530. 10.1158/1078-0432.CCR-04-1285CrossRefPubMed

28.

Odegaard E, Staff AC, Kaern J, Florenes VA, Kopolovic J, Trope CG, Abeler V, Reich R, Davidson B: The AP-2gamma transcription factor is upregulated in advanced-stage ovarian carcinoma. Gynecol Oncol. 2006, 100: 462-8. 10.1016/j.ygyno.2005.09.022CrossRefPubMed

29.

Pauls K, Jager R, Weber S, Wardelmann E, Koch A, Buttner R, Schorle H: Transcription factor AP-2gamma, a novel marker of gonocytes and seminomatous germ cell tumors. Int J Cancer. 2005, 115: 470-477. 10.1002/ijc.20913CrossRefPubMed

30.

Weber S, Biermann K, Schorle H: Transcription factor AP-2gamma essential for germ cell development [Abstract]. 6th Copenhagen Workshop on CIS Testis and Germ Cell Cancer. 2006,

31.

Robinson LL, Gaskell TL, Saunders PT, Anderson RA: Germ cell specific expression of c-kit in the human fetal gonad. Mol Hum Reprod. 2001, 7: 845-852. 10.1093/molehr/7.9.845CrossRefPubMed

32.

Hoyer PE, Byskov AG, Mollgard K: Stem cell factor and c-Kit in human primordial germ cells and fetal ovaries. Mol Cell Endocrinol. 2005, 234: 1-10. 10.1016/j.mce.2004.09.012CrossRefPubMed

33.

Inoue M, Kyo S, Fujita M, Enomoto T, Kondoh G: Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors. Cancer Res. 1994, 54: 3049-3053.PubMed

34.

Tsuura Y, Hiraki H, Watanabe K, Igarashi S, Shimamura K, Fukuda T, Suzuki T, Seito T: Preferential localization of c-kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma and seminoma/dysgerminoma in human: immunohistochemical study on formalin-fixed, paraffin-embedded tissues. Virchows Arch. 1994, 424: 135-141. 10.1007/BF00193492CrossRefPubMed

35.

Sever M, Jones TD, Roth LM, Karim FW, Zheng W, Michael H, Hattab EM, Emerson RE, Baldridge LA, Cheng L: Expression of CD117 (c-kit) receptor in dysgerminoma of the ovary: diagnostic and therapeutic implications. Mod Pathol. 2005, 18: 1411-1416. 10.1038/modpathol.3800463CrossRefPubMed

36.

Nakai Y, Nonomura N, Oka D, Shiba M, Arai Y, Nakayama M, Inoue H, Nishimura K, Aozasa K, Mizutani Y, Miki T, Okuyama A: KIT (c-kit oncogene product) pathway is constitutively activated in human testicular germ cell tumors. Biochem Biophys Res Commun. 2005, 337: 289-296. 10.1016/j.bbrc.2005.09.042CrossRefPubMed

37.

Scully RE: Gonadoblastoma; a gonadal tumor related to the dysgerminoma (seminoma) and capable of sex-hormone production. Cancer. 1953, 6: 455-463. 10.1002/1097-0142(195305)6:3<455::AID-CNCR2820060303>3.0.CO;2-UCrossRefPubMed

38.

Pauls K, Franke FE, Buttner R, Zhou H: Gonadoblastoma: evidence for a stepwise progression to dysgerminoma in a dysgenetic ovary. Virchows Arch. 2005, 447: 603-609. 10.1007/s00428-005-1272-9CrossRefPubMed

39.

Schnieders F, Dork T, Arnemann J, Vogel T, Werner M, Schmidtke J: Testis-specific protein, Y-encoded (TSPY) expression in testicular tissues. Hum Mol Genet. 1996, 5: 1801-1807. 10.1093/hmg/5.11.1801CrossRefPubMed

40.

Honecker F, Stoop H, De Krijger RR, Chris Lau YF, Bokemeyer C, Looijenga LH: Pathobiological implications of the expression of markers of testicular carcinoma in situ by fetal germ cells. J Pathol. 2004, 203: 849-857. 10.1002/path.1587CrossRefPubMed

41.

Boon T, Coulie PG, van den Eynde B: Tumor antigens recognized by T cells. Immunol Today. 1997, 18: 267-268. 10.1016/S0167-5699(97)80020-5CrossRefPubMed

42.

Satie AP, Rajpert-De Meyts E, Spagnoli GC, Henno S, Olivo L, Jacobsen GK, Rioux-Leclercq N, Jegou B, Samson M: The cancer-testis gene, NY-ESO-1, is expressed in normal fetal and adult testes and in spermatocytic seminomas and testicular carcinoma in situ. Lab Invest. 2002, 82: 775-780.CrossRefPubMed

43.

Aubry F, Satie AP, Rioux-Leclercq N, Rajpert-De Meyts E, Spagnoli GC, Chomez P, De Backer O, Jegou B, Samson M: MAGE-A4, a germ cell specific marker, is expressed differentially in testicular tumors. Cancer. 2001, 92: 2778-2785. 10.1002/1097-0142(20011201)92:11<2778::AID-CNCR10125>3.0.CO;2-SCrossRefPubMed

44.

Gaskell TL, Esnal A, Robinson LL, Anderson RA, Saunders PT: Immunohistochemical profiling of germ cells within the human fetal testis: identification of three subpopulations. Biol Reprod. 2004, 71: 2012-2021. 10.1095/biolreprod.104.028381CrossRefPubMed

45.

Yakirevich E, Sabo E, Lavie O, Mazareb S, Spagnoli GC, Resnick MB: Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms. Clin Cancer Res. 2003, 9: 6453-6460.PubMed

46.

Abeler V, Kjorstad KE, Nesland JM: Small cell carcinoma of the ovary. A report of six cases. Int J Gynecol Pathol. 1988, 7: 315-329.CrossRefPubMed

47.

Lifschitz-Mercer B, David R, Dharan M, Czernobilsky B: Small cell carcinoma of the ovary: an immunohistochemical and ultrastructural study with a review of the literature. Virchows Arch A Pathol Anat Histopathol. 1992, 421: 263-270. 10.1007/BF01611184CrossRefPubMed

48.

Moller H, Evans H: Epidemiology of gonadal germ cell cancer in males and females. APMIS. 2003, 111: 43-46. 10.1034/j.1600-0463.2003.11101071.xCrossRefPubMed

49.

Jorgensen N, Muller J, Jaubert F, Clausen OP, Skakkebaek NE: Heterogeneity of gonadoblastoma germ cells: similarities with immature germ cells, spermatogonia and testicular carcinoma in situ cells. Histopathology. 1997, 30: 177-186. 10.1046/j.1365-2559.1997.d01-580.xCrossRefPubMed

50.

Kinoshita K, Isozaki K, Hirota S, Nishida T, Chen H, Nakahara M, Nagasawa Y, Ohashi A, Shinomura Y, Kitamura Y, Matsuzawa Y: c-kit gene mutation at exon 17 or 13 is very rare in sporadic gastrointestinal stromal tumors. J Gastroenterol Hepatol. 2003, 18: 147-151. 10.1046/j.1440-1746.2003.02911.xCrossRefPubMed

Title: Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markers
Authors: Christina E Hoei-Hansen
Sigrid M Kraggerud
Vera M Abeler
Janne Kærn
Ewa Rajpert-De Meyts
Ragnhild A Lothe
Publication date: 01-12-2007
Publisher: BioMed Central
Published in: Molecular Cancer / Issue 1/2007
Electronic ISSN: 1476-4598
DOI: https://doi.org/10.1186/1476-4598-6-12

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2007

Breast cancer metastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-κB activation

Some facts and thoughts: p73 as a tumor suppressor gene in the network of tumor suppressors

In vivo optical imaging of integrin αV-β3 in mice using multivalent or monovalent cRGD targeting vectors

Expression of LIM kinase 1 is associated with reversible G1/S phase arrest, chromosomal instability and prostate cancer

Sodium Ascorbate induces apoptosis in neuroblastoma cell lines by interfering with iron uptake

Identification of novel androgen receptor target genes in prostate cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer